Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study
| Autor: | George A. Alba, Gabor Kovacs, Ronald H. Goldstein, Tufik R. Assad, Gaurav Choudhary, Horst Olschewski, Ryan J. Tedford, Gérald Simonneau, Bradley A. Maron, Bradley M. Wertheim, Stephen W. Waldo, Marc Humbert, Anna E. Barón, Jane A. Leopold, Evan L. Brittain, Shi Huang, Nazzareno Galiè, Edward Hess |
|---|---|
| Přispěvatelé: | Maron B.A., Brittan E.L., Hess E., Waldo S.W., Baron A.E., Huang S., Goldstein R.H., Assad T., Wertheim B.M., Alba G.A., Leopold J.A., Olschewski H., Galie N., Simonneau G., Kovacs G., Tedford R.J., Humbert M., Choudhary G. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Elevated pulmonary artery pressure Hypertension Pulmonary Kaplan-Meier Estimate 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine.artery medicine Humans Pulmonary vascular resistance 030212 general & internal medicine Pulmonary wedge pressure Aged Retrospective Studies business.industry Hazard ratio Retrospective cohort study Middle Aged Prognosis medicine.disease Survival Analysis Pulmonary hypertension medicine.anatomical_structure 030228 respiratory system Heart failure Pulmonary artery Cardiology Vascular resistance Vascular Resistance business |
| Popis: | Background: In pulmonary hypertension subgroups, elevated pulmonary vascular resistance (PVR) of 3·0 Wood units or more is associated with poor prognosis. However, the spectrum of PVR risk in pulmonary hypertension is not known. To address this area of uncertainty, we aimed to analyse the relationship between PVR and adverse clinical outcomes in pulmonary hypertension. Methods: We did a retrospective cohort study of all patients undergoing right heart catheterisation (RHC) in the US Veterans Affairs health-care system (Oct 1, 2007–Sep 30, 2016). Patients were included in the analyses if data from a complete RHC and at least 1 year of follow-up were available. Both inpatients and outpatients were included, but individuals with missing mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure, or cardiac output were excluded. The primary outcome measure was time to all-cause mortality assessed by the Veteran Affairs vital status file. Cox proportional hazards models were used to assess the association between PVR and outcomes, and the mortality hazard ratio was validated in a RHC cohort from Vanderbilt University Medical Center (Sept 24, 1998–June 1, 2016). Findings: The primary cohort (N=40 082; 38 751 [96·7%] male; median age 66·5 years [IQR 61·1–73·5]; median follow-up 1153 days [IQR 570–1971]), included patients with a history of heart failure (23 201 [57·9%]) and chronic obstructive pulmonary disease (13 348 [33·3%]). We focused on patients at risk for pulmonary hypertension based on a mPAP of at least 19 mm Hg (32 725 [81·6%] of 40 082). When modelled as a continuous variable, the all-cause mortality hazard for PVR was increased at around 2·2 Wood units compared with PVR of 1·0 Wood unit. Among patients with a mPAP of at least 19 mm Hg and pulmonary artery wedge pressure of 15 mm Hg or less, the adjusted hazard ratio (HR) for mortality was 1·71 (95% CI 1·59–1·84; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|